In a Tough IPO Market, a Marriage of Convenience
Firms are getting creative in the midst of suddenly dormant public markets.
With the IPO market still in a deep freeze, we thought it would be interesting to revisit a rather unique deal that closed last week involving Cardiovascular Systems (CSII) and Replidyne. When the two companies announced back in November 2008 they were merging, we found it to be somewhat of an oddity because these two firms have little in common. Replidyne focused its efforts on anti-infective drugs, while Cardiovascular Systems, which had filed to go public in early 2008, had developed a novel system to fight peripheral arterial disease, which is the buildup of plaque in vessel walls that can severally restrict blood circulation. With no obvious up-front synergies apparent to us, we deemed it to be a desperation move; a firm with a potentially viable product but no cash merges with another company with ample liquidity but lacking a product as a result of multiple failures. At the same time, this deal was a creative alternative, a work-around to the suddenly dormant public markets. So the question remains: Does a deal of this kind make sense?
When we established coverage on Cardiovascular Systems back in August 2008 as part of our IPO service, we deemed it an exciting growth story with a chance for success, albeit one facing several hurdles. The company's Diamondback 360 system is designed to attack the buildup of plaque and other fatty deposits by sanding it down into smaller particles that would then be removed by the bloodstream. We believe the system to be quite innovative and that it could become a viable alternative to current treatment methods such as stents and balloons.
Bill Buhr does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.